Newmont R&D increased by 4.7% to $45.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.7%, from $43.00M to $45.00M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 1.9% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $37.00M | $40.00M | $46.00M | $44.00M | $45.00M | $80.00M | $60.00M | $35.00M | $44.00M | $53.00M | $68.00M | $53.00M | $49.00M | $47.00M | $48.00M | $43.00M | $40.00M | $40.00M | $43.00M | $45.00M |
| QoQ Change | — | +8.1% | +15.0% | -4.3% | +2.3% | +77.8% | -25.0% | -41.7% | +25.7% | +20.5% | +28.3% | -22.1% | -7.5% | -4.1% | +2.1% | -10.4% | -7.0% | +0.0% | +7.5% | +4.7% |
| YoY Change | — | — | — | — | +21.6% | +100.0% | +30.4% | -20.5% | -2.2% | -33.8% | +13.3% | +51.4% | +11.4% | -11.3% | -29.4% | -18.9% | -18.4% | -14.9% | -10.4% | +4.7% |